An increasing number of pharma companies are going ‘beyond the pill’ to improve...
- Digital health highlights in neurology in 2017
- DCB trial results: a positive sign for Boston Scientific’s US market entry
- Microelectronic medical implants market worth $57.12 billion by 2025
- Top digital advances for immunology in 2017
- Robotic surgery markets are growing faster than humans can handle
DCB trial results: a positive sign for Boston Scientific’s US market entry
On 31 January 2018, Boston Scientific announced results from a first-of-its-kind trial comparing its Ranger drug-coated balloon (DCB) to Medtronic’s In.Pact Admiral DCB, revealing no statistical difference in patency rates between the two balloons. With such promising results, will this change the competitive landscape in the DCB market?
J&J purchases French surgical robotics firm Orthotaxy
Johnson and Johnson ( J&J) Medical Devices Companies, through its division Apsis, has acquired French surgical technologies developer Orthotaxy for an undisclosed amount.
Shire, Microsoft and EURORDIS to reduce rare disease diagnosis time
Shire has formed a strategic collaboration with Microsoft and EURORDIS-Rare Diseases Europe, a non-profit organisation, to minimise the time-to-diagnosis for children suffering from rare diseases.
Microelectronic medical implants market worth $57.12 billion by 2025
The global microelectronics medical implants market will be worth $57.12 billion by 2025, with a compound annual growth rate (CAGR) of 9.8% during the forecast period, according to a report by Grand View Research.
Cook Biotech signs deal for Aziyo Bio Envelope scaffold
US-based medical equipment developer Cook Biotech has signed exclusive worldwide global licence agreements for the use of Aziyo Biologics’ Bio Envelope scaffold with neuromodulation devices.
Medical Device Single Audit Programme – Practical Training for Medical Device Manufactures
The MDSAP Medical Device Single Audit Programme Practical Training for Medical Device Manufacturers is taking place on 21 March.
Edwards Lifesciences secures CE-Mark for Centera heart valve
US-based medical equipment firm Edwards Lifesciences has secured the European CE-Mark for the use of its self-expanding heart valve, Centera, in severe, symptomatic aortic stenosis patients who are at high risk of open-heart surgery.
Read our magazine
Medical Technology is the essential reading material for decision-makers in the medical device industry, bringing you the latest news and analysis in an exciting, interactive format.